Julia A. Steele

Julia A. Steele

Auto-generated profile, based on publicly available information

Julia A. Steele

Cancer Biology Program, Vanderbilt University, Nashville, TN, 37232, USA

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 October 2025 in Clinical Cancer Research
Verified
Journal Article
Closed access
ECErica V. Carballo
Erica V. Carballo
PGPaula Gonzalez-Ericsson
Paula Gonzalez-Ericsson
BLBrian Lehmann
Brian Lehmann
BTBrandie C. Taylor
Brandie C. Taylor
JWJulia D. Wulfkuhle
Julia D. Wulfkuhle
CPCourtney A. Penn
Courtney A. Penn
Purpose: Immune checkpoint inhibitors (ICI) have increasing application in endometrial cancer, underscoring the need for robust biomarkers for patient selection. JAK1 pathogenic variants (PV) have previously been implicated in immune evasion. In this study, we identify biomarkers predictive of ICI response in endometrial cancer and the implications of JAK1 PVs in this context. Experimental Design: This is a translational study of tumors from 84 patients with endometrial cancer treated with ICIs. High-throughput proteomic-based profiling was used to quantify 193 phosphoprotein/protein expression levels, including key JAK/STAT signaling pathway components. Associations with clinical outcomes were assessed using multivariate regression analysis. The functional consequences of JAK1 PVs were explored through in vitro signaling assays and analyses of The Cancer Genome Atlas database. Results: MHC-I expression correlated with improved progression-free survival (P = 0.035), validated in orthogonal approaches. Notably, a subset of patients harboring JAK1 PVs demonstrated exceptional survival on ICIs. In The Cancer Genome Atlas cohort of microsatellite instability–high and DNA polymerase epsilon–mutated tumors, homozygous loss of JAK1 trended toward decreased survival, whereas heterozygous loss of JAK1 was associated with significantly improved survival (P = 0.026), suggesting partial retention of antigen presentation pathways. Among our ICI-treated microsatellite instability–high tumor samples, NK cell marker NCAM1 was associated with improved survival (P = 0.02). Conclusions: These data support MHC-I as a potential predictive biomarker for ICI response in endometrial cancer. Additionally, we show that partial retention of JAK1 signaling in JAK1 tumors with heterozygous loss is associated with improved survival, potentially attributable to enhanced NK cell activity in tumors with low MHC-I expression.

22 April 2026 in Science Translational Medicine
Verified
Journal Article
Closed access
XSXiaopeng Sun
Xiaopeng Sun
AOAndres A. Ocampo
Andres A. Ocampo
AHAnn Hanna
Ann Hanna
BTBrandie C. Taylor
Brandie C. Taylor
JMJacey L. Marshall
Jacey L. Marshall
JBJustin M. Balko
Justin M. Balko
Dynamic biomarkers of therapy response are critical for precision oncology but often rely on serial tissue biopsies, which are invasive and not always feasible. In contrast, peripheral blood offers a minimally invasive, dynamic window into the evolving systemic immune landscape. Leveraging this, we performed RNA sequencing on 546 peripheral blood samples from 160 patients with high-risk stage II/III human epidermal growth factor receptor 2 (HER2)–negative breast cancer treated with either chemotherapy alone or in combination with immunotherapy (chemoimmunotherapy). Our analysis uncovered immune correlates of tumor subtype and treatment response. For example, samples from patients with triple-negative breast cancer exhibited elevated T cell receptor clonality and robust immune activation profiles. Among patients receiving chemoimmunotherapy, early responders demonstrated high baseline T cell receptor diversity, followed by rapid clonal expansion and activation of T cells after just one treatment cycle. We developed a multiparametric peripheral immune biomarker that integrated baseline and early on-treatment features to predict response to pembrolizumab, which was successfully validated in an independent cohort of 59 patients with breast cancer treated with neoadjuvant dostarlimab. These findings reveal the potential of blood-based immune monitoring to predict immunotherapy benefit, offering an accessible tool for tailoring treatment strategies in breast cancer.

30 April 2026 in Biomaterials
Verified
Journal Article
Open access
JSJacob A. Schulman
Jacob A. Schulman
KAKaran Arora
Karan Arora
AKAlexander J. Kwiatkowski
Alexander J. Kwiatkowski
NCNeil C. Chada
Neil C. Chada
JSJulia A. Steele
Julia A. Steele
JWJohn T. Wilson
John T. Wilson
The stimulator of interferon genes (STING) pathway is a promising immuno-oncology target. Despite their potential, STING agonists have yielded underwhelming results in clinical trials due to pharmacological barriers that limit their safety and efficacy. Herein, we describe the design and pre-clinical evaluation of a polymeric dimeric amidobenzimidazole (diABZI) STING agonist delivery platform for cancer immunotherapy. Central to our technology is a stimuli-responsive diABZI-functionalized reversible addition-fragmentation chain transfer (RAFT) polymerization chain transfer agent (CTA) that allows well-defined polymer chains to be grown directly from a single STING agonist. Using a biocompatible poly(N,N'-dimethylacrylamide) polymer as a first-generation scaffold and a disulfide as a clinically relevant linker, we demonstrate our platform liberates a potent diABZI analog under reducing conditions to trigger STING-driven inflammatory gene expression in tumors, thereby stimulating antitumor immunity in multiple murine models and synergizing with α-PD-1 immune checkpoint blockade to eliminate tumors. This work therefore establishes a promising delivery platform for microenvironmental regulation of STING activation with promise as an immunotherapy for cancer.


15 December 2025
Verified
Other
Open access
ECErica V. Carballo
Erica V. Carballo
PGPaula Gonzalez-Ericsson
Paula Gonzalez-Ericsson
BLBrian Lehmann
Brian Lehmann
BTBrandie C. Taylor
Brandie C. Taylor
JWJulia D. Wulfkuhle
Julia D. Wulfkuhle
CPCourtney A. Penn
Courtney A. Penn
Purpose:Immune checkpoint inhibitors (ICI) have increasing application in endometrial cancer, underscoring the need for robust biomarkers for patient selection. JAK1 pathogenic variants (PV) have previously been implicated in immune evasion. In this study, we identify biomarkers predictive of ICI response in endometrial cancer and the implications of JAK1 PVs in this context.Experimental Design:This is a translational study of tumors from 84 patients with endometrial cancer treated with ICIs. High-throughput proteomic-based profiling was used to quantify 193 phosphoprotein/protein expression levels, including key JAK/STAT signaling pathway components. Associations with clinical outcomes were assessed using multivariate regression analysis. The functional consequences of JAK1 PVs were explored through in vitro signaling assays and analyses of The Cancer Genome Atlas database.Results:MHC-I expression correlated with improved progression-free survival (P = 0.035), validated in orthogonal approaches. Notably, a subset of patients harboring JAK1 PVs demonstrated exceptional survival on ICIs. In The Cancer Genome Atlas cohort of microsatellite instability–high and DNA polymerase epsilon–mutated tumors, homozygous loss of JAK1 trended toward decreased survival, whereas heterozygous loss of JAK1 was associated with significantly improved survival (P = 0.026), suggesting partial retention of antigen presentation pathways. Among our ICI-treated microsatellite instability–high tumor samples, NK cell marker NCAM1 was associated with improved survival (P = 0.02).Conclusions:These data support MHC-I as a potential predictive biomarker for ICI response in endometrial cancer. Additionally, we show that partial retention of JAK1 signaling in JAK1 tumors with heterozygous loss is associated with improved survival, potentially attributable to enhanced NK cell activity in tumors with low MHC-I expression.